Wiedmann, Melina http://orcid.org/0000-0001-7250-4329
Kuitunen-Paul, Sören
Basedow, Lukas Andreas http://orcid.org/0000-0003-4866-8686
Wolff, Max
DiDonato, Nataliya
Franzen, Julia
Wagner, Wolfgang
Roessner, Veit http://orcid.org/0000-0002-1873-7081
Golub, Yulia
Article History
Received: 7 December 2021
Revised: 2 June 2022
Accepted: 9 June 2022
First Online: 6 August 2022
Competing interests
: The authors declare the following financial interests/personal relationships which may be considered as potential conflicts of interest: For SK-P, grants and non-financial support during the past 36 months were outside of the scope of the submitted work. Veit Roessner has received payment for consulting and writing activities from Lilly, Novartis, and Shire Pharmaceuticals, lecture honoraria from Lilly, Novartis, Shire Pharmaceuticals/Takeda, and Medice Pharma, and support for research from Shire Pharmaceuticals/Takeda and Novartis. Veit Roessner has carried out or is currently carrying out clinical trials in cooperation with the Novartis, Shire Pharmaceuticals/Takeda, Servier and Otsuka companies. All cooperations were outside of the scope of the submitted work. Wolfgang Wagner is cofounder of Cygenia GmbH (ExternalRef removed), which provides service for epigenetic analysis to other scientists and was involved in this study. Julia Franzen contributes to this company, too. MW, LAB, NDD, MW, and YG declare no competing interests.
: The Institutional Review Board of the University Hospital C. G. Carus Dresden (EK 66022018) approved all procedures. Participants and their legal guardians were informed about the projects. Written informed consent was obtained from all legal guardians.